U.S. senators want clinical trials to include more women; Ranbaxy recalls allergy med;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: ICYMI this week: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: Taro expanding a plant in Canada. Provincial government will kick in about $10M of the $247M investment. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Takeda wins $70M from Japan to bump up H5N1 vaccine production. FierceVaccines story | Follow @CarlyHFierce

> Women senators from both parties are pressing the FDA to do more to ensure that more women are included in clinical research. Story

> The FDA is launching a Mini-Sentinel review of the safety concerns of Astellas' overactive bladder treatment, Myrbetriq. Announcement

> Ranbaxy Laboratories is recalling nearly 30,000 packs of its allergy med, oratadine, and pseudoephedrine sulphate extended release tablets made by its Ohm Laboratories plant because of packaging problems. Story

> BioMarin ($BMRN) is adding 50 new jobs to its Dublin Global Commercial Operation Hub in Ireland. Report

> The FDA's proposed rule to classify e-cigarettes as tobacco products may seem counterintuitive, but is certainly more accommodating than its earlier attempt to ban them. Blog Post

Medical Device News

@FierceMedDev: Veracyte is advancing into Brazil with its thyroid cancer Dx through an interesting new partnership. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Updated with statement from company: Intuitive gets out from under FDA warning letter. Report | Follow @VarunSaxena2

@EmilyWFierce: More bad news for Endo: Company posted net losses of $436.9M and a drop in pharma sales in Q1. FiercePharma story | Follow @EmilyWFierce

@MichaelGFierce: ICYMI from FierceDrugDelivery: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Article | Follow @MichaelGFierce

> CardioDx revives IPO plans with infusion of fresh leadership. More

> Mainstay Medical raises $25M in European IPO. Story

> GI Dynamics bags $32M in private placement. Item

Biotech News

@FierceBiotech: EuroBiotech: Britain fearful of Pfizer future, UCB on the hunt for antibody partners, Novartis snubs Transgene. Report | Follow @FierceBiotech

@JohnCFierce: Vintafolide is toast, fails PhIII. Release | Follow @JohnCFierce

@DamianFierce: $AGN says it's "golf-course deprived" but stays mum on rumored bouncey castle, ski ball machine and raw juice bar. More from the WSJ | Follow @DamianFierce

@EmilyMFierce: Looking to sales growth, Merck rolls out vaccine adherence plan. More from FierceVaccines | Follow @EmilyMFierce

> FDA rejects The Medicines Co.'s clot-buster, sending cangrelor back to the clinic. News

> Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal. More

> AstraZeneca bars the door, but Pfizer presses on with $106B buyout bid. Report

> Ex-champ Vertex dumps hep C, but shares spike on positive CF results. Story

And Finally... Citing the effects of regulatory action by the U.S. FDA on Indian drugmakers, an Indian official says the government will work with the industry on a branding campaign to shine up its tarnished image. Story

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.